iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
The Neuralink details malfunction in first human brain-chip implant story concerns partial electrode-thread retraction, not total implant failure. Neuralink said some flexible threads moved back from Noland Arbaugh’s brain in the weeks after his January 2024 surgery, reducing effective electrodes and temporarily lowering cursor performance. The company reported software compensation, but not the exact thread count or definitive cause.
Key takeaways
- Neuralink reported that some of the 64 flexible threads in its N1 implant retracted from the brain, reducing the number of electrodes producing useful signals.
- Neuralink said the thread problem temporarily reduced cursor-control performance, but it did not say that the entire implant stopped working or that the implant was removed.
- Neuralink reported that algorithm, decoding, and interface changes restored and eventually exceeded Noland Arbaugh’s initial performance; that result has not been independently audited or peer-reviewed in the cited record.
- The company did not disclose how many threads moved, why they moved, whether any tissue injury occurred, or whether the threads returned to their original positions.
- PRIME remains an FDA-authorized investigational early-feasibility study, not an FDA-approved consumer product or routine medical treatment.
What happened to Neuralink’s first human brain-chip implant?
Neuralink disclosed on May 8, 2024, that “a number of threads” in the implant used by its first human participant had retracted from his brain during the weeks after surgery. The movement reduced the number of electrodes that were effectively recording neural activity and caused a decline in measured cursor-control performance.
The participant was Noland Arbaugh, who has quadriplegia resulting from a spinal-cord injury. Arbaugh received Neuralink’s investigational N1 implant in January 2024 at Barrow Neurological Institute in Phoenix, Arizona, as part of the company’s PRIME Study. Neuralink said Arbaugh went home the day after surgery. The company’s description of the PRIME implant and first implantation provides the technical and clinical background.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →The most accurate description is a partial mechanical problem affecting electrode threads. The public disclosure does not support saying that the chip came loose, that all 64 threads were pulled out, that the entire implant failed, or that Arbaugh was injured by the event.
Popular on Amazon
| Question | What the public record supports | What remains unknown |
|---|---|---|
| Did the whole implant fail? | No. Neuralink said the system remained usable. | The long-term condition of every component and channel. |
| What moved? | Some flexible electrode threads retracted from the brain. | The exact number, distance, and extent of displacement. |
| What was the immediate effect? | Fewer effective electrodes and temporarily lower cursor-control performance. | The precise change in signal quality and channel redundancy. |
| Was the implant removed? | Neuralink said it was not removed. | Whether any additional clinical intervention or monitoring was required. |
| Was the problem repaired? | Neuralink adapted software and reported improved performance. | Whether the underlying mechanical issue was physically reversed. |
How does the Neuralink N1 implant work?
The N1 is a fully implantable, wireless, rechargeable intracortical brain-computer interface. Electrodes on flexible threads record neural activity in the motor cortex. Electronics in the implant process and transmit the data wirelessly to an external computer running Neuralink software, where neural signals are decoded into commands such as cursor movement.
According to Neuralink’s PRIME Study progress update, the N1 contains 1,024 electrodes distributed across 64 flexible threads. Each thread is thinner than a human hair. The threads are delicate enough that Neuralink uses the R1 surgical robot to insert them rather than relying on ordinary manual placement.
The architecture creates a trade-off. Flexible threads can be placed individually in different brain locations and may reduce some mechanical stress compared with a rigid array. Flexibility also makes the threads difficult to handle, position, and stabilize inside living tissue that moves relative to the skull and implant. A small positional change can alter which neurons an electrode detects.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsThe threads are therefore not merely wiring between the brain and the implant. They are the part of the system that directly interfaces with brain tissue. Retraction can reduce the number of useful channels, change the signal pattern available to decoding software, and raise questions about long-term mechanical stability.
How did thread retraction affect Arbaugh’s performance?
Neuralink said the reduction in effective electrodes initially lowered Arbaugh’s measured cursor-control speed, expressed in bits per second. Bits per second is a measure of how quickly and accurately a user can communicate information through a control system; it is not a direct measure of health, intelligence, or overall quality of life.
In its May 2024 user-experience update, Neuralink reported an initial cursor-control result of 4.6 bits per second and a later peak of 8.0 bits per second. Neuralink said Arbaugh used the system for as many as roughly eight hours per weekday in research sessions and more than 10 hours on some weekends, with a reported total of 69 hours in one week across structured and personal use.
Neuralink attributed the subsequent improvement to three software-side changes:
- Making the recording algorithm more sensitive to signals from populations of neurons.
- Improving the techniques used to translate neural activity into cursor movement.
- Enhancing the user interface.
Neuralink described the result as a “rapid and sustained improvement” that surpassed Arbaugh’s initial performance. The wording matters: software compensation can make use of remaining channels or a changed signal pattern more efficiently, but software improvement does not demonstrate that displaced threads returned to their original locations or that the hardware problem was physically repaired.
Neuralink also reported that Arbaugh used the system to control a computer cursor and play online chess and Sid Meier’s Civilization VI. Those demonstrations show that the system remained functional for particular tasks. They do not, by themselves, establish long-term safety, stable performance across users, or recovery of every affected electrode.
Also popular on Amazon
Was Noland Arbaugh injured?
Neuralink’s public update said the surgery went well and Arbaugh’s recovery was smooth. The company did not report a direct injury associated with the thread retraction and said it handled the issue through system refinements rather than implant removal.
“No reported injury,” however, is not the same as proof that the event was harmless. The available public material does not independently establish whether tissue injury, inflammation, infection, hemorrhage, persistent displacement, or another clinical effect occurred. The available record also does not say whether Arbaugh required additional medical monitoring or intervention.
A careful conclusion is therefore: Neuralink did not report a direct injury in its public account, but the available disclosure does not establish the full clinical significance of the retraction. PRIME is an early-feasibility study precisely because safety and function must be evaluated over time in human participants.
Why might Neuralink’s electrode threads have retracted?
The public Neuralink disclosure described the event but did not provide a definitive cause. Several mechanisms are technically plausible, but none should be presented as the established explanation for Arbaugh’s case.
- Normal movement of the brain relative to the skull-mounted implant.
- Movement between the implant and the surface of the brain.
- Excess tension, insufficient slack, or changes in thread geometry.
- Tissue healing, contraction, or other biological responses.
- Mechanical forces during implantation or after surgery.
- The depth, angle, or geometry of thread insertion.
Neuralink’s later update about its second participant said the company reduced brain motion during surgery and reduced the gap between the implant and the brain’s surface. Those changes suggest that Neuralink considered positioning and motion relevant engineering factors. They do not prove that either factor alone caused Arbaugh’s retraction.
Neuralink’s own discussion of building safe implantable devices also acknowledges that a significant tissue reaction around inserted threads could degrade neural-signal detection and decoding and could potentially compromise patient safety. That statement describes a general device risk; it does not demonstrate that such a reaction occurred in Arbaugh’s case.
What did Neuralink change for the second participant?
In an August 21, 2024 update, Neuralink said it introduced measures intended to reduce the probability of thread retraction in its second participant, identified as Alex. The reported changes were reduced brain motion during surgery and a smaller gap between the implant and the brain’s surface.
Neuralink said it observed no thread retraction in the second participant at the time of that update. Neuralink also said Arbaugh’s threads had stabilized and that his performance had recovered. Both statements are company-reported outcomes rather than findings from an independent clinical report or a peer-reviewed publication.
The second-participant changes are encouraging evidence that the company responded to the first implant’s behavior. They are not proof that the design issue has been solved for every participant or that the threads will remain stable over multi-year follow-up.
Also popular on Amazon
What is the timeline of Neuralink’s PRIME study?
| Date | Event | Significance |
|---|---|---|
| May 2023 | FDA Investigational Device Exemption authorization for PRIME, according to Neuralink. | The company could study the device in people under an approved investigational protocol; this was not market approval. |
| September 2023 | PRIME recruitment began, according to Neuralink. | The first-in-human study began enrolling eligible participants. |
| January 2024 | Noland Arbaugh received the first human N1 implant at Barrow Neurological Institute. | This was Neuralink’s first human implantation, not the first human brain-computer interface ever implanted. |
| April 12, 2024 | Neuralink described early use of the system. | The company highlighted cursor control and computer interaction. |
| May 8, 2024 | Neuralink disclosed that some threads had retracted. | The company reported fewer effective electrodes and a temporary performance decline. |
| August 21, 2024 | Neuralink described design and surgical mitigations for participant two. | The company said it had reduced brain motion and the implant-to-brain gap. |
| February 5, 2025 | Neuralink later reported three PRIME participants and aggregate usage in its “A Year of Telepathy” update. | Later enrollment and usage reports did not replace the need for detailed, independently assessed safety results. |
| January 9, 2026 | The ClinicalTrials.gov record for PRIME was updated. | The retrieved registry record listed no posted study results. |
The ClinicalTrials.gov record for PRIME, NCT06429735, describes the study as evaluating the safety and functionality of the N1 Implant and R1 Robot in participants with tetraparesis or tetraplegia. The record remains the appropriate place to distinguish trial registration and status from promotional progress updates.
Recommended Free Tools
What remains unknown about the Neuralink malfunction?
The central disclosure gap is the missing number. Neuralink said that “a number of threads” retracted, but it did not publicly quantify the affected threads or the resulting number of lost or nonfunctional electrodes. Without that information, readers cannot calculate the percentage of the 64 threads affected, assess the loss of channel redundancy, or compare the event’s severity with other implant failures.
The public account also does not establish:
- The exact cause of the retraction.
- Whether the threads completely withdrew or were only partly displaced.
- Whether imaging, operative evidence, or other clinical measurements confirmed the position change.
- Whether any tissue damage, inflammation, infection, or hemorrhage occurred.
- Whether the displaced threads remained partially functional.
- Whether the event was formally classified as an adverse event under the study’s regulatory reporting system.
- Whether the software gains reflected hardware recovery, user learning, algorithmic adaptation, interface changes, or a combination of those factors.
- Whether the first-participant mitigation will remain effective over years rather than weeks or months.
The absence of those details does not prove that Neuralink concealed a serious injury or that the device is unsafe. It does mean that the public cannot independently determine the event’s full clinical significance from the company’s updates alone.
Does thread retraction undermine Neuralink’s broader clinical program?
The incident is a meaningful engineering and clinical warning, but it is not evidence that Neuralink’s entire brain-computer-interface program failed. A system that continued to produce useful cursor control after a partial channel loss demonstrates some software adaptability and signal redundancy. At the same time, the event exposes a core challenge for intracortical implants: the signal-acquisition interface must remain stable inside moving, healing biological tissue.
Flexible intracortical threads offer potential benefits, including high electrode counts and individually distributed recording sites. The same design introduces risks involving insertion, tension, micromotion, tissue reaction, signal drift, and long-term anchoring. Software can compensate for some signal changes, but software cannot eliminate the need to show that the implanted hardware remains safe and reliable.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Later reports of additional participants or improved usage should therefore be read as progress signals, not as substitutes for complete clinical evidence. The strongest evaluation would require transparent participant-level safety information, long-term follow-up, clearly defined performance measures, and independent analysis.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Is Neuralink’s implant FDA approved?
No. Neuralink’s N1 and R1 system was investigational in the cited records. Neuralink announced that the PRIME study received an FDA Investigational Device Exemption in May 2023, and the company opened the first clinical trial for recruitment under that framework.
An IDE permits an investigational medical device to be studied in human participants under specified conditions and protections. An IDE is not the same as FDA clearance or approval to market a device for general sale or routine clinical use. The FDA’s clinical-studies guidance and its early-feasibility-study framework explain the regulatory context for first-in-human device research.
As of the supplied January 9, 2026 ClinicalTrials.gov record update, PRIME remained an investigational early-feasibility study, and no study results were posted on the retrieved registry record. The implant was not a consumer brain chip available for ordinary purchase.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Also popular on Amazon
Was Neuralink the first human brain-computer implant?
Neuralink’s January 2024 surgery was the company’s first human implantation, but it was not the first human brain-computer interface ever implanted. Academic groups and other companies had previously conducted human BCI research.
Neuralink’s particular contribution combines a fully implanted wireless device, flexible intracortical threads, robotic insertion, and computer-cursor control. Describing the event as Neuralink’s first human implant is accurate. Describing it as the first human brain implant or the first human BCI generally would be inaccurate.
What is the precise bottom line?
Neuralink did not report that its entire brain implant failed. Neuralink reported that some electrode threads pulled back from Arbaugh’s brain, reducing the number of effective recording electrodes and temporarily degrading cursor-control performance. Neuralink said software, decoding, and interface changes restored performance, but the company did not disclose the number of displaced threads or a definitive cause.
The incident therefore has two simultaneous meanings. It was not a total system shutdown, and the participant reportedly continued using the implant. It was also a significant warning about the mechanical stability and clinical risks of placing flexible electrodes in brain tissue. Until detailed, independently evaluated, long-term results are available, the fairest conclusion is that the system showed useful resilience while its underlying implant stability remained an open clinical question.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallFrequently Asked Questions
Did Neuralink’s first brain implant completely fail?
No. Neuralink reported partial retraction of some flexible electrode threads, not failure of the entire N1 implant. Neuralink said the system remained usable after software and interface changes.
How many Neuralink electrode threads retracted?
Neuralink did not publicly disclose the exact number of retracted threads or the number of affected electrodes. The company described the problem only as involving “a number of threads.”
Was Noland Arbaugh injured by the Neuralink thread problem?
Neuralink did not report a direct injury in its public update, but the available disclosure does not establish the full clinical significance of the retraction. Public materials do not independently resolve questions about tissue injury, inflammation, infection, or long-term stability.
Did Neuralink fix the retracted threads?
Neuralink said it modified recording algorithms, signal-decoding techniques, and the user interface, after which performance improved. Those changes compensated for the altered signal environment; they do not prove that the displaced threads physically returned to their original positions.
Free tools Windows power users keep installed
One-click scans. No signup required.
Is Neuralink’s N1 brain implant available to consumers?
No. The N1 and R1 system remained investigational in the cited records and was being studied through the FDA-authorized PRIME early-feasibility trial. An Investigational Device Exemption permits human research under specified conditions but is not FDA approval for general sale or routine clinical use.
The Bottom Line
Bottom line: Neuralink reported a partial electrode-thread retraction in its first human participant, not a total brain-implant failure. The system reportedly continued to control a cursor after software compensation, but the missing thread count, unknown cause, and lack of independently posted long-term results prevent a definitive judgment about the event’s safety or whether the design problem is solved.

